...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Rock Stars still rocking it

I've listened to the presentation twice and it sure gives me a feeling of hope.

In terms of cohort definitions Don's comments related to page 16 (Trial Design) in the top blue rectangle suggests 3 planned dosage levels all with the same enzalutimide dosage. So I assume the 5 chorts are dosage levels.

However, I did email Sarah and asked for specific definitions just to be sure.

It does seem quite positive.

I did not see or hear any indication that ZCC or ZEG will be sold in the next couple of months or that there will be liquidity soon.

Toinv

Share
New Message
Please login to post a reply